Hermann Hauser
Co-founder, Director, and Venture Partner @ Amadeus Capital Partners
Cambridge, United Kingdom
Hermann Hauser is a Series A investor at Amadeus Capital Partners in Cambridge focused on Artificial Intelligence and Information Technology. Hermann Hauser is the Co-founder, Director, and Venture Partner of Amadeus Capital Partners. He previously worked at IXI as a Founder. Hermann Hauser attended the University of Vienna.
- Total investments:
- 102
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries Hermann Hauser invests in
Stages Hermann Hauser invests in
Countries Hermann Hauser invests in
Round sizes
Round size
- Seed
- $1.1M–$6.5M
- Series A
- $1.3M–$22M
- Series B
- $10M–$40M
Investment Focus
Industry
- Artificial Intelligence 14 (14%)
- Information Technology 13 (13%)
- Software 12 (12%)
- Machine Learning 12 (12%)
- Biotechnology 10 (10%)
Stage
- Series A 21 (21%)
- Seed 18 (18%)
- Series B 12 (12%)
- Venture - Series Unknown 12 (12%)
- Funding Round 9 (9%)
Country
- United Kingdom 20 (20%)
- Austria 10 (10%)
- Germany 4 (4%)
- The Netherlands 4 (4%)
- Italy 3 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xeltis
|
A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $23.3M / Venture - Series Unknown / Jul 28, 2026 | |
Leyden Labs
|
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $45.4M / Jun 25, 2026 | |
H2SITE
|
Systems and Membranes for high efficiency and purity Hydrogen production i.e. for Separation or Ammonia cracking | Series B / Jun 24, 2026 | |
CroíValve
|
CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $20M / Series B / Jun 23, 2026 | |
Slamcore
|
SLAMcore’s mission is to make commercial-grade spatial intelligence accessible to allTheir team of world-leading spatial intelligence experts have developed advanced SLAM (simultaneous localization and mapping) software that allow robots and drones to truly understand the space around them.Spun out from Imperial College London, SLAMcore hascreated real-time, commercial grade, location, mapping and perception (SLAM) software for use in autonomous robots, drones and consumer products. The SLAMcore software enables fast prototyping and development of commercial products using visual SLAM software for autonomous location, mapping and perception. The software runs in real-time on standard compute/sensors and can be customised for commercial products using cost-effective custom compute/sensors. The team includes industry leading SLAM experts, roboticists, engineers and developers. Pushing the boundaries of what's possible today and how visual SLAM will look like tomorrow. Through partnership with OEMs, SLAMcore provides the core technology that allows robots to become a meaningful part of everyday life. | $14M / May 27, 2026 | |
D-CRBN
|
D-CRBN Operator of a climate technology company that aims to transform carbon into sustainable raw resources. | $20.4M / Series A / May 26, 2026 | |
TILT Biotherapeutics
|
TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolyticviruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors. | $25.3M / Series B / May 13, 2025 | |
VSPARTICLE
|
VSPARTICLE develops nanoparticle generators for various applications such as sensors, batteries, catalysis, solar cells, healthcare, additive manufacturing, nano safety, and more. It also enables research and industry to generate new materials at the push of a button.They specialize in nanoparticle production and integration. The technologyspeeds up the developments of customers by producing the desired nanoparticles on location and integrate them directly in the final product. VSPARTICLE was founded in 2014 and is headquartered in Delft, The Netherlands. | $7.1M / Series A / Aug 08, 2024 | |
Riverlane
|
Riverlane creates and engineers instruments. With the help of the manufacturers of quantum computers, they put them into practice. New hardware and software tools are needed to regulate intrinsically unstable qubits and completely fix system defects ten billion times or more per second in order to unlock the entire range of quantum computingapplications. | $75M / Series C / Aug 06, 2024 | |
Fractile
|
Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale. | $14.8M / Seed / Jun 18, 2024 | |
| See all 102 investments → | |||
Co-Investors
Molten Ventures
13 deals together
Parkwalk Advisors
10 deals together
eQventure
9 deals together
Foundation Capital
8 deals together
IQ Capital
7 deals together
University of Cambridge Enterprise
7 deals together
About Amadeus Capital Partners
Amadeus Capital is a global technology investor that invests in technology companies at all stages, from seed to venture buyout; they also buy stakes from other investors or founders, to ensure that companies and entrepreneurs have the runway they need to succeed. They invest in a broad variety of sectors including enterprise and infrastructuresoftware, consumer and business services, medical technology and healthcare IT, and cleantech and resource efficiency.It has the imagination to see where new businesses can be created and the technical insight, operational experience and global network to help entrepreneurs make their vision a reality.The Company was founded in 1997 and since has backed more than 130 companies and raised over $1bn for investment.
Amadeus Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amelia Armour
Partner, Early Stage Funds
|
|||
Anne Glover
CEO
|
|||
Nick Kingsbury
Partner
|
|||
Andrea Traversone
Managing Partner
|
|||
|
Hermann Hauser
Co-founder, Director, and Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Hermann Hauser invest in?
Hermann Hauser invests primarily in Artificial Intelligence, Information Technology and Software startups, most often at Series A and Seed stage. Most of the 102 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Hermann Hauser's check size?
Hermann Hauser typically joins rounds of $1.1M–$6.5M at Seed, $1.3M–$22M at Series A and $10M–$40M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hermann Hauser participates in.
When did Hermann Hauser last invest?
The most recent investment recorded for Hermann Hauser closed in Jul 2026. Shizune tracks 102 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
